Earnings Releases·Nov 5, 2026, 4:05 PM ET

Accendra Health — Third Quarter 2026 Earnings Summary

Net revenue declined 13.7% year-over-year to $601.8 million in Q3 2026, while GAAP and Non-GAAP losses widened significantly compared to the prior year's income.
Full-year 2026 guidance was lowered to the bottom of the previous range ($2.45–$2.55 billion), with adjusted EBITDA forecast to potentially fall 30% below the prior midpoint.
The company is executing a sale of its Products & Healthcare Services business and a value creation plan to return to profitability, though it cannot forecast GAAP measures due to unpredictable restructuring and acquisition charges.
Balance sheet optimization included a reduction in total debt to $1.75 billion, though cash reserves dropped to $26.6 million and interest expense rose to $37.6 million in Q3.
Management acknowledged results have fallen short of expectations, citing macro conditions and market risks, while noting a $33 million gain on a non-core asset sale and a $51 million gain on patient service equipment.